Director Joseph D. Keegan filed a Form 4 with the SEC on November 2, 2026, disclosing the acquisition of 2,750 shares of BIO-TECHNE Corp common stock on October 29, 2026, at a price of $0, along with the grant of new stock options.

Key Highlights

  • Transaction: Joseph D. Keegan, a director of BIO-TECHNE Corp (NASDAQ:TECH), acquired 2,750 shares of common stock on October 29, 2026, at a price of $0 per share via transaction code A.
  • Post-transaction ownership: Following the transaction, Keegan directly owns 18,161 shares of BIO-TECHNE common stock.
  • New stock options granted: Keegan received stock options to purchase 3,777 shares of common stock at an exercise price of $60.96, exercisable from October 29, 2026, with an expiration date of October 30, 2035.
  • Total stock options held: Keegan holds nine series of stock options covering a combined total of 51,381 underlying shares, with exercise prices ranging from $31.26 to $128.81.
  • Filing signed: The form was signed by Andrew Nick as Attorney-in-Fact for Joseph D. Keegan pursuant to a previously filed Power of Attorney, dated November 2, 2026.

Director Keegan's October 2026 Share Acquisition and Option Grant at BIO-TECHNE

According to the Form 4 filed on November 2, 2026, Joseph D. Keegan, a director of BIO-TECHNE Corp, reported the acquisition of 2,750 shares of the company's common stock on October 29, 2026, at a price of $0 per share, coded as transaction type "A." Following this acquisition, the filing reports that Keegan directly and beneficially owns 18,161 shares of BIO-TECHNE common stock.

The filing also discloses that on October 29, 2026, Keegan received stock options to purchase 3,777 shares of BIO-TECHNE common stock at an exercise price of $60.96 per share. These options became exercisable on October 29, 2026, and are set to expire on October 30, 2035, according to the filing. This new grant brings Keegan's total reported stock option holdings across nine separate series to 51,381 underlying shares, with exercise prices ranging from $31.26 (exercisable from October 25, 2018, expiring October 26, 2027) to $128.81 (exercisable from October 27, 2022, expiring October 28, 2031).

The form was filed by Andrew Nick as Attorney-in-Fact for Joseph D. Keegan pursuant to a Power of Attorney previously filed with the SEC. No derivative securities transactions were reported in Table II beyond the pre-existing and newly granted stock option positions listed.

What Was Disclosed

BIO-TECHNE Corp director Joseph D. Keegan reported acquiring 2,750 shares of common stock at $0 on October 29, 2026, bringing his direct holdings to 18,161 shares, and disclosed a new grant of stock options for 3,777 shares at $60.96 expiring October 30, 2035.